Techasatian Leelawadee, Komwilaisak Patcharee, Panombualert Sunee, Uppala Rattapon, Jetsrisuparb Charoon
Division of Dermatology, Department of Pediatric, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
Department of Pediatric, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
Acta Paediatr. 2016 Jun;105(6):e257-62. doi: 10.1111/apa.13378. Epub 2016 Apr 8.
The aim of this study was to explore the efficacy and safety of propranolol in treating infantile haemangiomas, the most common benign vascular tumours in children.
We carried out a retrospective chart review of infantile haemangioma patients admitted to the Faculty of Medicine, Khon Kaen University, Thailand, from January 2009 to January 2015.
There were 53 infantile haemangioma cases treated with oral propranolol. Treatment responses occurred as early as two weeks after propranolol administration in 91.5% of the follow-up patients, with all 53 cases achieving the desired treatment responses two months after propranolol was initiated. No significant differences in treatment responses were found between propranolol as a mono-therapy or as a combination therapy with prednisolone at the two-week (p value 0.13) and one-month follow-ups (p value 0.98). Complications were documented in three cases (5.6%) when the propranolol dose was increased, and these were asymptomatic hypoglycaemia in two cases and one case of hypotension.
Propranolol was effective in treating infantile haemangiomas, and combining it with prednisolone achieved no significant differences in treatment outcome. Cases should be monitored for hypoglycaemia and hypotension. More data on using propranolol for infantile haemangiomas are needed, including long-term follow-up studies.
本研究旨在探讨普萘洛尔治疗婴儿血管瘤（儿童最常见的良性血管肿瘤）的疗效和安全性。
我们对2009年1月至2015年1月期间泰国孔敬大学医学院收治的婴儿血管瘤患者进行了回顾性病历审查。
53例婴儿血管瘤患者接受了口服普萘洛尔治疗。91.5%的随访患者在服用普萘洛尔后两周内出现治疗反应，所有53例患者在开始服用普萘洛尔两个月后均达到预期治疗反应。在两周（p值0.13）和一个月随访时，普萘洛尔单药治疗或与泼尼松龙联合治疗的治疗反应无显著差异（p值0.98）。当普萘洛尔剂量增加时，有3例（5.6%）出现并发症，其中2例为无症状低血糖，1例为低血压。
普萘洛尔治疗婴儿血管瘤有效，与泼尼松龙联合使用在治疗效果上无显著差异。应监测患者是否出现低血糖和低血压。需要更多关于使用普萘洛尔治疗婴儿血管瘤的数据，包括长期随访研究。
